ITCI stock forecast
Our latest prediction for Intra-Cellular Therapies, Inc.'s stock price was made on the Jan. 9, 2020 when the stock price was at 25.43$.
In the short term (2weeks), ITCI's stock price should underperform the market by -5.29%. During that period the price should oscillate between -11.83% and +12.49%.
In the medium term (3months), ITCI's stock price should underperform the market by -7.79%. During that period the price should oscillate between -39.08% and +31.71%.Get email alerts
Create a solid portfolio with ITCI
About Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -2.69$ per share.
The book value per share is 7.14$
Three months stock forecastJan. 9, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|